📰 Rachel Eides News
Page 4 - Rachel Eides News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rachel Eides. Real-time updates on events, politics, business and more.
February 3, 2022
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) - read this article along with other careers information, tips and advice on BioSpace
April 10, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel ... CRISPR Therapeutics AGApril 10, 2021 GMT ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Compan...
March 11, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer ... CRISPR Therapeutics AGMarch 10, 2021 GMT ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the A...
February 5, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day CRISPR Therapeutics AGFebruary 5, 2021 GMT ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team...
December 17, 2020
Cerevel Therapeutics to Host Inaugural Virtual R&D Event Cerevel Therapeutics to Host Inaugural Virtual R&D Event Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST CAMBRIDGE, Mass., Dec. 14, 2020 — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced i...